Bharat Biotech, which completed the Phase 2/3 trials of COVID-19 vaccine Covaxin for use in children under 18 years of age last week, has received the Subject Expert Committee’s nod for administering the drug to kids.
The Hyderabad-based biotechnology company had last week submitted the data to the Central Drugs Standard Control Organisation for its verification and subsequent approval for Emergency Use Authorisation for the jab.
With this, Covaxin becomes the first COVID-19 vaccine that can be administered to children in India.
Meanwhile, the World Health Organisation (WHO) is yet to take a call on granting Emergency Use Listing (EUL) status for Covaxin. The global health body is likely to a final call this week.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor.